Zacks.com on MSN2d
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
HIV Diagnostics Market worth $5.31 billion by 2030
The global HIV diagnostics market, valued at US$2.96B in 2024, is forecasted to grow at a 10.3% CAGR, reaching US$3.25B by ...
The Manila Times8d
Molecular Infectious Disease Testing Market to Hit US$17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust ...
DelveInsight Business Research, LLP: Global In Situ Hybridization Market to Grow at a CAGR of ~7% by 2032 | DelveInsight
The demand for in situ hybridization is experiencing significant growth, mainly due to the rising rates of cancer and genetic disorders. This trend is further driven by the increasing incidence ...
Yahoo Finance16d
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?
Despite the dip, the company has still performed better than its peers, Exact Sciences EXAS and QIAGEN QGEN ... CoV-2 Assay is an in vitro diagnostic test that detects SARS-CoV-2 RNA from ...